Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Stephanie K. Montgomery"'
Autor:
David T. Huang, Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Kevin E. Kip, Oscar C. Marroquin, Stephen Koscumb, Kevin Collins, Judith A. Shovel, Mark Schmidhofer, Mary Kay Wisniewski, Colleen Sullivan, Donald M. Yealy, Meredith Axe, David A. Nace, Ghady Haidar, Tina Khadem, Kelsey Linstrum, Graham M. Snyder, Christopher W. Seymour, Stephanie K. Montgomery, Bryan J. McVerry, Lindsay Berry, Scott Berry, Russell Meyers, Alexandra Weissman, Octavia M. Peck-Palmer, Alan Wells, Robert Bart, Debbie L. Albin, Tami Minnier, Derek C. Angus
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Abstract Objectives The primary objective is to evaluate the comparative effectiveness of COVID-19 specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) Emergency Use Authorization (EUA), alongside UPMC Health System effort
Externí odkaz:
https://doaj.org/article/11a244af7e12486d9480802ecb95cd0a
Autor:
Patrick R. Lawler, Rob Fowler, Edward Litton, Colin McArthur, Katrina Orr, Ryan Zarychanski, Christopher W. Seymour, Richard Beasley, Herman Goossens, Timothy D. Girard, John C. Marshall, Rachael Parke, Marc J. M. Bonten, Susan C. Morpeth, Lennie P. G. Derde, Abi Beane, Steven Y. C. Tong, Alisa Higgins, Asad E. Patanwala, Jane C. Parker, Anna McGlothlin, Menno de Jong, Shay McGuinness, Stephanie K. Montgomery, Alistair Nichol, Frank L. van de Veerdonk, Zahra Bhimani, Christopher M. Horvat, Allen C. Cheng, Manu Shankar-Hari, Anthony C. Gordon, Ewan C. Goligher, Farah Al Beidh, Lise J Estcourt, Kelsey Linstrum, Salim Malakouti, Andrew J King, Michelle A. Detry, Bryan J. McVerry, Francois Lamontagne, Rashan Haniffa, Alexis F. Turgeon, Srinivas Murthy, Cameron Green, Yaseen M. Arabi, Paul R Mouncey, Lolowa Al Swaidan, Eamon Duffy, Lindsay R. Berry, Roger J. Lewis, Scott M. Berry, Kathryn M Rowan, Djillali Annane, Christina Saunders, Meredith Buxton, Mark Fitzgerald, Anne Turner, Elizabeth Lorenzi, Adrian Buzgau, Derek C. Angus, David T. Huang, Charlotte Bradbury, Steven A R Webb, Marlene Santos, Daniel F. McAuley, Thomas Hills, Frank M. Brunkhorst
Publikováno v:
Intensive care medicine
Intensive Care Medicine, 47, 8, pp. 867-886
Investigators, REMAP-CAP & Dark, P 2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. ', Intensive care medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial ', Intensive Care Medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
Intensive care medicine, vol 47, iss 8
Arabi, Y M 2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial ', Intensive Care Medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
Intensive Care Medicine, 47, 867-886
Intensive care medicine, 47(8), 867-886. Springer Verlag
INTENSIVE CARE MEDICINE
Intensive Care Medicine
Intensive Care Medicine, 47, 8, pp. 867-886
Investigators, REMAP-CAP & Dark, P 2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. ', Intensive care medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial ', Intensive Care Medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
Intensive care medicine, vol 47, iss 8
Arabi, Y M 2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial ', Intensive Care Medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
Intensive Care Medicine, 47, 867-886
Intensive care medicine, 47(8), 867-886. Springer Verlag
INTENSIVE CARE MEDICINE
Intensive Care Medicine
Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 were randomized to receive lopinavir-ritonavir, hydroxychloro
Autor:
Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Judith A. Shovel, Mary Kay Wisniewski, Michelle Adam, Debbie Albin, Tami Minnier, Mark Schmidhofer, Russell Meyers, Oscar C. Marroquin, Kevin Collins, William Garrard, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Kelsey Linstrum, Anna Nakayama, Stephanie K. Montgomery, Graham M. Snyder, Donald M. Yealy, Derek C. Angus, Paula L. Kip, Christopher W. Seymour, David T. Huang, Kevin E. Kip
Publikováno v:
JAMA network open. 5(4)
Monoclonal antibody (mAb) treatment decreases hospitalization and death in high-risk outpatients with mild to moderate COVID-19; however, only intravenous administration has been evaluated in randomized clinical trials of treatment. Subcutaneous admi
Autor:
Erin K. McCreary, J. Ryan Bariola, Tami E. Minnier, Richard J. Wadas, Judith A. Shovel, Debbie Albin, Oscar C. Marroquin, Kevin E. Kip, Kevin Collins, Mark Schmidhofer, Mary Kay Wisniewski, David A. Nace, Colleen Sullivan, Meredith Axe, Russell Meyers, Alexandra Weissman, William Garrard, Octavia M. Peck-Palmer, Alan Wells, Robert D. Bart, Anne Yang, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Tina Khadem, Kelsey Linstrum, Stephanie K. Montgomery, Daniel Ricketts, Jason N. Kennedy, Caroline J. Pidro, Ghady Haidar, Graham M. Snyder, Bryan J. McVerry, Donald M. Yealy, Derek C. Angus, Anna Nakayama, Rachel L. Zapf, Paula L. Kip, Christopher W. Seymour, David T. Huang
Publikováno v:
Contemporary clinical trials. 119
Monoclonal antibodies (mAb) that neutralize SARS-CoV-2 decrease hospitalization and death compared to placebo in patients with mild to moderate COVID-19; however, comparative effectiveness is unknown. We report the comparative effectiveness of bamlan
Autor:
David T. Huang, Erin K. McCreary, J. Ryan Bariola, Tami E. Minnier, Richard J. Wadas, Judith A. Shovel, Debbie Albin, Oscar C. Marroquin, Kevin E. Kip, Kevin Collins, Mark Schmidhofer, Mary Kay Wisniewski, David A. Nace, Colleen Sullivan, Meredith Axe, Russell Meyers, Alexandra Weissman, William Garrard, Octavia M. Peck-Palmer, Alan Wells, Robert D. Bart, Anne Yang, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Tina Khadem, Kelsey Linstrum, Stephanie K. Montgomery, Daniel Ricketts, Jason N. Kennedy, Caroline J. Pidro, Rachel L. Zapf, Paula L. Kip, Ghady Haidar, Graham M. Snyder, Bryan J. McVerry, Donald M. Yealy, Derek C. Angus, Christopher W. Seymour
IMPORTANCEThe effectiveness of monoclonal antibodies (mAbs), casirivimab and imdevimab, and sotrovimab, for patients with mild to moderate COVID-19 from the Delta variant is unknown.OBJECTIVETo evaluate the effectiveness of mAbs for the Delta variant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48ad3dc1fcec7da4462d0339f3315cd0
https://doi.org/10.1101/2021.12.23.21268244
https://doi.org/10.1101/2021.12.23.21268244
Autor:
Richard J. Wadas, Mary Kay Wisniewski, Lindsay R. Berrry, Scott M. Berry, Anna McGlothlin, Anna Nakayama, Christopher W. Seymour, Judith A Shovel, Donald M. Yealy, Mark Schmidhofer, Erin K McCreary, Kevin E. Kip, Tami Minnier, Stephanie K. Montgomery, Derek C. Angus, David T. Huang, Kelsey Linstrum, William Garrard, Paula L Kip, Oscar C. Marroquin, Debbie Albin, Kevin Collins, Michelle Adam, Graham M. Snyder, Russell Meyers, Amy M. Crawford, J Ryan Bariola
ImportanceMonoclonal antibody (mAb) treatment decreases hospitalization and death in outpatients with mild to moderate COVID-19; however, only intravenous administration has been evaluated in randomized clinical trials of treatment. Subcutaneous admi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d9b8ba79e9a9f2e325d1ad2e5b301ba
https://doi.org/10.1101/2021.11.30.21266756
https://doi.org/10.1101/2021.11.30.21266756
Autor:
Scott M. Berry, Tina Khadem PharmD, David A. Nace, Daniel Ricketts Mt, Alexandra Weissman, Kevin E. Kip, Robert Bart, Russell Meyer, Jason N Kennedy Ms, Graham M. Snyder, Stephanie K Montgomery Ms, Meredith Axe Bs, Tami Minnier Ms, Ghady Haidar, William Garrard, J Ryan Bariola, Colleen Sullivan Mha, Bryan J. McVerry, Kelsey Linstrum Ms, Octavia M Peck-Palmer, Alan Wells, Paula L Kip, Lindsay R. Berry, Dave T Huang, Richard J. Wadas, Judith A Shovel, Anne Yang, Kevin Collins, Anna McGlothin, Oscar C. Marroquin, Amy M. Crawford, Caroline J Pidro Bs, Derek C. Angus, Mark Schmidhofer, Erin K McCreary PharmD, Christopher W. Seymour, Mary K Wisniewski Ma, Debbie L Albin Bs
BackgroundNeutralizing monoclonal antibodies (mAb) targeting SARS-CoV-2 decrease hospitalization and death in patients with mild to moderate Covid-19. Yet, their clinical use is limited, and comparative effectiveness is unknown.MethodsWe present the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d331ec780e2e75f2d615f4d06b82668
https://doi.org/10.1101/2021.09.03.21262551
https://doi.org/10.1101/2021.09.03.21262551
Autor:
Kelsey Linstrum, Ghady Haidar, David A. Nace, Russell Meyers, Stephanie K. Montgomery, Donald M. Yealy, Lindsay R. Berry, Colleen Sullivan, Richard J. Wadas, Tami Minnier, Kevin E. Kip, Meredith Axe, Alexandra Weissman, J Ryan Bariola, Robert Bart, Mark Schmidhofer, Octavia M Peck-Palmer, Mary Kay Wisniewski, Debbie Albin, Derek C. Angus, Alan Wells, David T. Huang, Christopher W. Seymour, Graham M. Snyder, Bryan J. McVerry, Judith A Shovel, Tina Khadem, Erin K McCreary, Stephen Koscumb, Kevin Collins, Oscar C. Marroquin, Scott M. Berry
Publikováno v:
Trials
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Objectives The primary objective is to evaluate the comparative effectiveness of COVID-19 specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) Emergency Use Authorization (EUA), alongside UPMC Health System efforts to incr
Autor:
David T. Huang, Erin K. McCreary, J. Ryan Bariola, Tami E. Minnier, Richard J. Wadas, Judith A. Shovel, Debbie Albin, Oscar C. Marroquin, Kevin E. Kip, Kevin Collins, Mark Schmidhofer, Mary Kay Wisniewski, David A. Nace, Colleen Sullivan, Meredith Axe, Russell Meyers, Alexandra Weissman, William Garrard, Octavia M. Peck-Palmer, Alan Wells, Robert D. Bart, Anne Yang, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Tina Khadem, Kelsey Linstrum, Stephanie K. Montgomery, Daniel Ricketts, Jason N. Kennedy, Caroline J. Pidro, Anna Nakayama, Rachel L. Zapf, Paula L. Kip, Ghady Haidar, Graham M. Snyder, Bryan J. McVerry, Donald M. Yealy, Derek C. Angus, Christopher W. Seymour
Publikováno v:
JAMA Network Open. 5:e2220957
The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-CoV-2 Delta variant.To evaluate the effectiveness of mAb against the Delta variant compa
Autor:
Judith A Shovel, Christopher W. Seymour, Oscar C. Marroquin, Mary Kay Wisniewski, Richard J. Wadas, Ghady Haidar, Stephen Koscumb, Tami Minnier, Erin K McCreary, Mark Schmidhofer, Stephanie K. Montgomery, Kevin E. Kip, Tina Khadem, Derek C. Angus, Bariola, David T. Huang, Kevin Collins, Sullivan C, Kelsey Linstrum, David A. Nace, Graham M. Snyder, Donald M. Yealy
BackgroundMonoclonal antibody (mAb) treatment may prevent complications of COVID-19. We sought to quantify the impact of bamlanivimab monotherapy on hospitalizations and mortality, as well as Emergency Department (ED) visits without hospitalization,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c73d162f751b310e4badf056e84bb1f8
https://doi.org/10.1101/2021.03.25.21254322
https://doi.org/10.1101/2021.03.25.21254322